Cargando…

An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains

The objective was to develop a method of HCV genome sequencing that allowed simultaneous genotyping and NS5A inhibitor resistance profiling. In order to validate the use of a unique RT-PCR for genotypes 1–5, 142 plasma samples from patients infected with HCV were analysed. The NS4B-NS5A partial regi...

Descripción completa

Detalles Bibliográficos
Autores principales: Andre-Garnier, Elisabeth, Besse, Bernard, Rodallec, Audrey, Ribeyrol, Olivier, Ferre, Virginie, Luco, Caroline, Le Guen, Laura, Bourgeois, Nathalie, Gournay, Jérôme, Billaud, Eric, Raffi, François, Coste-Burel, Marianne, Imbert-Marcille, Berthe-Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519038/
https://www.ncbi.nlm.nih.gov/pubmed/28727784
http://dx.doi.org/10.1371/journal.pone.0179562
_version_ 1783251572538474496
author Andre-Garnier, Elisabeth
Besse, Bernard
Rodallec, Audrey
Ribeyrol, Olivier
Ferre, Virginie
Luco, Caroline
Le Guen, Laura
Bourgeois, Nathalie
Gournay, Jérôme
Billaud, Eric
Raffi, François
Coste-Burel, Marianne
Imbert-Marcille, Berthe-Marie
author_facet Andre-Garnier, Elisabeth
Besse, Bernard
Rodallec, Audrey
Ribeyrol, Olivier
Ferre, Virginie
Luco, Caroline
Le Guen, Laura
Bourgeois, Nathalie
Gournay, Jérôme
Billaud, Eric
Raffi, François
Coste-Burel, Marianne
Imbert-Marcille, Berthe-Marie
author_sort Andre-Garnier, Elisabeth
collection PubMed
description The objective was to develop a method of HCV genome sequencing that allowed simultaneous genotyping and NS5A inhibitor resistance profiling. In order to validate the use of a unique RT-PCR for genotypes 1–5, 142 plasma samples from patients infected with HCV were analysed. The NS4B-NS5A partial region was successfully amplified and sequenced in all samples. In parallel, partial NS3 sequences were analyzed obtained for genotyping. Phylogenetic analysis showed concordance of genotypes and subtypes with a bootstrap >95% for each type cluster. NS5A resistance mutations were analyzed using the Geno2pheno [hcv] v0.92 tool and compared to the list of known Resistant Associated Substitutions recently published. In conclusion, this tool allows determination of HCV genotypes, subtypes and identification of NS5A resistance mutations. This single method can be used to detect pre-existing resistance mutations in NS5A before treatment and to check the emergence of resistant viruses while undergoing treatment in major HCV genotypes (G1-5) in the EU and the US
format Online
Article
Text
id pubmed-5519038
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-55190382017-08-07 An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains Andre-Garnier, Elisabeth Besse, Bernard Rodallec, Audrey Ribeyrol, Olivier Ferre, Virginie Luco, Caroline Le Guen, Laura Bourgeois, Nathalie Gournay, Jérôme Billaud, Eric Raffi, François Coste-Burel, Marianne Imbert-Marcille, Berthe-Marie PLoS One Research Article The objective was to develop a method of HCV genome sequencing that allowed simultaneous genotyping and NS5A inhibitor resistance profiling. In order to validate the use of a unique RT-PCR for genotypes 1–5, 142 plasma samples from patients infected with HCV were analysed. The NS4B-NS5A partial region was successfully amplified and sequenced in all samples. In parallel, partial NS3 sequences were analyzed obtained for genotyping. Phylogenetic analysis showed concordance of genotypes and subtypes with a bootstrap >95% for each type cluster. NS5A resistance mutations were analyzed using the Geno2pheno [hcv] v0.92 tool and compared to the list of known Resistant Associated Substitutions recently published. In conclusion, this tool allows determination of HCV genotypes, subtypes and identification of NS5A resistance mutations. This single method can be used to detect pre-existing resistance mutations in NS5A before treatment and to check the emergence of resistant viruses while undergoing treatment in major HCV genotypes (G1-5) in the EU and the US Public Library of Science 2017-07-20 /pmc/articles/PMC5519038/ /pubmed/28727784 http://dx.doi.org/10.1371/journal.pone.0179562 Text en © 2017 Andre-Garnier et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Andre-Garnier, Elisabeth
Besse, Bernard
Rodallec, Audrey
Ribeyrol, Olivier
Ferre, Virginie
Luco, Caroline
Le Guen, Laura
Bourgeois, Nathalie
Gournay, Jérôme
Billaud, Eric
Raffi, François
Coste-Burel, Marianne
Imbert-Marcille, Berthe-Marie
An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains
title An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains
title_full An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains
title_fullStr An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains
title_full_unstemmed An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains
title_short An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains
title_sort ns5a single optimized method to determine genotype, subtype and resistance profiles of hepatitis c strains
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519038/
https://www.ncbi.nlm.nih.gov/pubmed/28727784
http://dx.doi.org/10.1371/journal.pone.0179562
work_keys_str_mv AT andregarnierelisabeth anns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT bessebernard anns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT rodallecaudrey anns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT ribeyrololivier anns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT ferrevirginie anns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT lucocaroline anns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT leguenlaura anns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT bourgeoisnathalie anns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT gournayjerome anns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT billauderic anns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT raffifrancois anns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT costeburelmarianne anns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT imbertmarcilleberthemarie anns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT andregarnierelisabeth ns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT bessebernard ns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT rodallecaudrey ns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT ribeyrololivier ns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT ferrevirginie ns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT lucocaroline ns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT leguenlaura ns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT bourgeoisnathalie ns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT gournayjerome ns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT billauderic ns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT raffifrancois ns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT costeburelmarianne ns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains
AT imbertmarcilleberthemarie ns5asingleoptimizedmethodtodeterminegenotypesubtypeandresistanceprofilesofhepatitiscstrains